Blood cancers

Up-front bortezomib improves response in newly-diagnosed myeloma

Treatment with bortezomib rather than thalidomide in newly-diagnosed multiple myeloma leads to deeper response rates but no improvement in survival, an interim analysis of Melbourne patients has concluded. Dr Adrian Chee, from Monash Haematology, and colleagues reviewed 59 patients treated with thalidomide-containing induction regimens from 2009, and 70 who received bortezomib-based regimens after its PBS ...

Already a member?

Login to keep reading.

© 2021 the limbic